Deep, targeted subsequent-generation sequencing has uncovered that subclonal mutations (i.e., Individuals current in only a portion of tumor cells) can be detected for all driver genes and therefore are related to swift disease progression and very poor outcome.11–13 This is particularly suitable for TP53 mutations given The reality that, as expl